Latest News

  • FDA Approves ARISTADA INITIO™ for the Initiation of ARISTADA® for Schizophrenia Read More
  • Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference Read More
  • Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program Read More

Investors

Working at Alkermes